Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service hernia repair cases in New Jersey: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 73 | 5,969 | 33% |
| 2020 | 45 | 4,639 | 36% |
| 2021 | 57 | 5,597 | 39% |
| 2022 | 78 | 5,853 | 41% |
| 2023 | 83 | 5,767 | 43% |
| 2024 | 76 | 5,785 | 45% |
| 2025 from claims | – | 5,607 5,145–5,932 | 46% |
| 2026 forecast | – | 5,697 5,013–6,574 | 46% |
| 2027 forecast | – | 5,776 4,938–6,883 | 47% |
| 2028 forecast | – | 5,855 4,886–7,169 | 47% |
| 2029 forecast | – | 5,935 4,848–7,443 | 47% |
| 2030 forecast | – | 6,016 4,820–7,709 | 48% |
Open, laparoscopic, and robotic ventral and inguinal hernia repair. Professional codes (what the surgeon bills): CPT 49505, 49650, 49651, 49560, 49561, 49565, 49566, 49570, 49572, 49585, 49587, 49590, 49652, 49653, 49654, 49655, 49656, 49657, 49591, 49592, 49593, 49594, 49595, 49596, 49613, 49614, 49615, 49616, 49617, 49618, 49621, 49622; the hospital bills MS-DRG 353, 354, 355.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 32% of the cases CMS names in New Jersey; 49 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 9% inpatient hospital, 86% hospital outpatient, 4% surgery center. The share outside the hospital has moved −4 pts since 2019.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 131 | 10,502−1.8%/yr | −1.8%/yr | 6.1 | 7% | 11,800 in 2030+1.9%/yr |
| Pennsylvania | 114 | 8,075−2.5%/yr | −2.5%/yr | 6.3 | 4% | 8,470 in 2030+0.8%/yr |
| Massachusetts | 66 | 5,037−2.7%/yr | −2.7%/yr | 5.6 | 1% | 5,860 in 2030+2.6%/yr |
| Connecticut | 25 | 1,918−2.5%/yr | −2.5%/yr | 6.2 | 0% | 2,470 in 2030+4.3%/yr |
| New Hampshire | 13 | 1,120−0.6%/yr | −0.6%/yr | 5.2 | 2% | 1,720 in 2030+7.5%/yr |
| Maine | 2 | 755−6.9%/yr | −6.9%/yr | 5.1 | 0% | 940 in 2030+3.8%/yr |
| Rhode Island | 6 | 457−5.4%/yr | −5.4%/yr | 5.4 | 0% | 350 in 2030−4.5%/yr |
| Vermont | 6 | 439+0.5%/yr | +0.5%/yr | 4.0 | 0% | 760 in 2030+9.5%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Cholecystectomy & appendectomy | 81 | 3,400−3.2%/yr | −3.2%/yr | 3.30.9× | 1% | 3,540 in 2030+0.7%/yr |
| Colorectal resection | 8 | 1,527−3%/yr | −3%/yr | 1.50.9× | 0% | 1,740 in 2030+2.2%/yr |
| Antireflux & hiatal hernia surgery | 7 | 492+0.3%/yr | +0.3%/yr | 0.50.7× | 0% | 540 in 2030+1.6%/yr |
| Breast reconstruction | 1 | 481−3.3%/yr | −3.3%/yr | 0.51.1× | 0% | 370 in 2030−4.1%/yr |
| Bariatric surgery | 0 | 168−20%/yr | −20%/yr | 0.20.9× | 0% | 120 in 2030−5%/yr |
Hernia repair in every state, and its device makers · Every procedure market in New Jersey · Every state · Compare with New York
BD leads with 27% of company spending on these surgeons in 2025, +2 pts on 2024.
In 2025, 8 companies reported engagement with New Jersey’s surgeons worth $114K in consulting, speaking, meals and travel tied to these products, about $1,505 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 5 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.